It has been shown that patients with rheumatic fever continue to produce antibodies to hemolytic streptococcus for months after the subsidence of an apparently transient respiratory infection. The various clinical types of rheumatic fever are accompanied by characteristic types of antibody response. In monocyclic attacks with acute onset, a period of severe illness, and relatively rapid recovery, the titer reaches maximum relatively early-within a month of the onset of rheumatic symptoms. In attacks with insidious onset, where repeated cycles of progressive severity culminate in severe carditis months later, the titer rises more gradually, reaching its maximum height late in the illness (1). This close relation between the course of antibody production and the clinical character of the rheumatic attack has stimulated us to investigate the underlying reason for the prolonged development of streptococcal antibody in this disease.
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The simple hypothesis that the infectious agent persists throughout the period of rising titer, does not lend itself to direct proof or disproof in the human subject. During convalescence from pharyngitis, hemolytic streptococcus commonly disappears from the mucosa of the upper respiratory tract, and only the occasional patient furnishes the opportunity to recover it later from deeper tissues, such as an accessory sinus, middle ear, or tonsils. The impossibility of thorough bacteriological studies of deep tissues in human subjects has obliged us to use an indirect approach to explain the significance of prolonged antibody development. The purpose of this paper is to summarize such indirect evidence as we have been able to obtain, and to indicate its bearing on the rheumatic fever problem. The data have been collected from naturally occurring throat infections in human subjects and from experimental infections in the guinea pig. One year later this patient again contracted pharyngitis with hemolytic streptococcus Group A (not typed). Two weeks after infection she complained of fatigue and vague abdominal pain (Cycle 1 of rheumatism). Five weeks after infection she developed chest pain, slight erythema marginatum, and tachycardia (Cycle 2), although these symptoms were mild and the blood sedimentation rate rose to 100 mm. per hour (Westergren). Five weeks after infection she developed severe precordial pain, polyarthritis and facial edema. This was the third cycle in the rheumatic attack but the first with frank clinical symptoms. There were four other classical cycles in the next four months. In contrast to the previous year the antistreptolysin titer rose slowly during this attack and did not reach its peak until about five to six months after infection.
This patient illustrates a characteristic relationship be- Anti-M precipitins are known to occur in nonrheumatic subjects following hemolytic streptococcal throat infections (2, 3). They generally appear and subside a little later than antistreptolysin, being maximal at about 5 weeks after the onset of infection (3). Anti-M precipitins also occur in the sera of rheumatic patients, but we have not followed the course of their development in relation to antistreptolysin except in a few isolated cases (3). We therefore conducted the following study. Procedure Sera were collected from rheumatic subjects at weekly intervals from the onset of pharyngitis over a period of three to six months. Sixteen individuals who developed rheumatic fever comprise the group reported in this study. Each sample of serum was tested in three ways. Antistreptolysin was titrated according to our standard procedure (4) . Anti-M type-specific precipitins were estimated according to Lancefield's method (5) . Typespecific agglutinins were estimated according to the slide agglutination technique originally described by Griffith (6) and used by ourselves (7), for the typing of hemolytic streptococcus. Type-specific M-substances for the precipitin tests were prepared by extracting cultures of the organism recovered from the patient's throat during the acute infection. The slide agglutination tests, were carried out on the patient's serum with suspensions of the patient's organism and with control suspensions of other serological types.
Resudts
All sixteen patients developed a striking rise in the antistreptolysin titer, and all developed type-specific antibodies. Fourteen showed precipitins and eleven gave slide agglutination reactions. The times when maximum titers occurred are shown in Table I . In the majority of cases antibody to the Msubstances continued to increase after the antistreptolysin titer had reached its maximum level. Hence any prolongation of the immune response in these patienfts affected both antibodies, and not antistreptolysin alone. These findings point to the prolonged activity of hemolytic streptococcus as a whole.
II. THE EFFECT OF POSTSTREPTOCOCCAL SEPTIC COMPLICATIONS ON ANTIBODY PRODUCTION
Preliminary observations on non-rheumatic subjects (3) indicated that in the absence of complications, maximum antistreptolysin titers were usually reached within three weeks after the onset of scarlet fever and pharyngitis. Subsequent studies have been made of a larger group of patients during recovery from streptococcal respiratory infections. Some of these had normal recoveries and others developed septic complications.
Eighty-five cases, including fifty-four of scarlet fever and thirty-one of pharyngitis, were studied from the onset of infection through convalescence, for periods varying from six to sixteen weeks. Of fifty-nine patients who had normal recoveries, fifty-seven reached their maximum titer within a month, and two were delayed beyond a month. Twenty-six patients had complications of varying degrees of severity. Of these, only fourteen reached maximum titer within a month. The data for patients with and without complications are presented in Table II.   TABLE II The number of patients reaching their maximum antistreptolysin titer at various times after the onset of streptococcal throat infections The development of a septic complication was followed in most cases by a further rise in antistreptolysin titer; and the time of this rise depended on when the complication appeared. Late increases in antibody titer occurred in fourteen patients. Twelve of these late rises were associated with demonstrable active infection.
In summary, it appeared that the antistreptolysin titer increased as long as the infectious agent continued to be active. The agar foci gave rise to abscesses which ruptured spontaneously and healed, as a rule, within 6 weeks. With healing, the titers either remained at plateau level without further rise for a number of weeks, or fell rapidly to zero.
Attempts were made to raise the titers of these guinea pigs still further by the injection of various nonspecific antigens. Filtrates from B. typhosus, B. Leptisepticus, and meningococcus were administered either intravenously, intrapericardially, subcutaneously, or intracutaneously. None of these materials had any effect on the antistreptolysin titer levels.
It was possible, however, to induce secondary rises in titer more than two months after the original focus, by the introduction of a new agar focus after the healing of the primary lesion. Fifteen guinea pigs were treated in this way, eight receiving the new focus before and seven receiving it after the titer induced by the first infection had subsided. Thirteen of these animals developed higher antistreptolysin titers after the healing of the second focus than they had shown after the first. Of the seven pigs whose second focus was given after the antibody titer to the first had subsided, six showed a greater response to the second focus than they had to the first. Five pigs received a third focus, which in each case gave rise to a new increase in titer. The effect of repeated foci on the antistreptolysin titers of guinea pigs is shown in Figure 2 .
In summary, the progressive development of high antistreptolysin levels in the guinea pig appeared dependent upon repeated infections with hemolytic streptococcus. The results of these cultures were as follows. No organisms were recovered from guinea pigs with stationary or falling titers, irrespective of when the animals were killed. The twelve pigs killed during the period of rising titer had viable organisms in the depths of the foci.
SUMMARY
Findings are presented which support the view that prolonged increases in streptococcal antibody, such as are observed in rheumatic fever, signify subclinical activity of hemolytic streptococcus.
